Digest Network Come funziona
Network
/
Società
IN
Non verificato

INVENTIVA

Di cosa scriviamo

FarmaceuticaPolitica Internazionale

66 comunicati stampa

Guarda tutti i comunicati
30/04/2025
Farmaceutica
Politica Internazionale
Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposition des documents préparatoires
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
30/04/2025
Farmaceutica
Politica Internazionale
Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2025
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
30/04/2025
Farmaceutica
Politica Internazionale
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
30/04/2025
Farmaceutica
Politica Internazionale
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
24/04/2025
Farmaceutica
Politica Internazionale
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
24/04/2025
Farmaceutica
Politica Internazionale
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
15/04/2025
Farmaceutica
Politica Internazionale
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F »)
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
15/04/2025
Farmaceutica
Politica Internazionale
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
01/04/2025
Farmaceutica
Politica Internazionale
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
01/04/2025
Farmaceutica
Politica Internazionale
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0